[Federal Register Volume 81, Number 152 (Monday, August 8, 2016)]
[Notices]
[Page 52452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-18689]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Department of Health and Human 
Services.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing and/or co-development in the 
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing and/or co-development.

ADDRESSES: Invention Development and Marketing Unit, Technology 
Transfer Center, National Cancer Institute, 9609 Medical Center Drive, 
Mail Stop 9702, Rockville, MD 20850-9702.

FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent 
applications listed below may be obtained by contacting: Attn. 
Invention Development and Marketing Unit, Technology Transfer Center, 
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, 
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email 
[email protected]. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.
    Title of invention: Synthetic Human-Derived Peptides and 
Peptidomimetics for Cancer Therapeutics
    Keywords: Rpn13, selective proteasome inhibitor, proteasome 
ubiquitin receptors, (competition: carfilzomib and bortezomib too 
toxic, resistance developed), solid tumors, hematological cancer, HPV 
associated cancer, ovarian cancer, prostate cancer, gastric cancer, 
breast cancer, or colorectal cancer
    Description of Technology: FDA approved 26S proteasome inhibitors, 
such as carfilzomib and bortezomib (Velcade[supreg]) have proven to be 
effective at treating hematologic cancers. However, resistance to these 
agents as well as their toxicity have raised concerns and highlight the 
need for new 26S proteasome inhibitors.
    Investigators at the NCI's Structural Biophysics Laboratory have 
developed a new class of proteasome inhibitors. They are hRpn2-derived 
peptides capable of specifically targeting the Pru domain of hRpn13. 
Disruption of the Rpn2/Rpn13 interaction inhibits proteolysis by a 
mechanism that differs from those of the approved proteasome 
inhibitors.
    Potential Commercial Applications:
     New class of proteasome inhibitors, targeting hRpn13 of 
the regulatory particle.
    Value Proposition:
     Synergistic with, and more specific than, known proteasome 
inhibitors.
     Alternate mechanism of action compared to approved 
proteasome inhibitors.
    Development Stage: Discovery (Lead ID).
    Inventor(s): Kylie J. Walters (NCI), Fen Liu (NCI), and Xiuxiu Lu 
(NCI).
    Intellectual Property:
    HHS Reference No. E-278-2015/0-US-01.
    US Provisional Application 62/222,530 (HHS Reference No. E-278-
2015) filed September 23, 2015 entitled ``Human RPN2 Derived Peptides 
Useful For Treating Cancer''.
    Publications: 1. Lu X., et al., 2015 PLoS One 2015 Oct 14;10(10) 
PMID: 26466095.
    Contact Information: Requests for copies of the patent application 
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D., 
email: [email protected].

    Dated: July 26, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National 
Cancer Institute.
[FR Doc. 2016-18689 Filed 8-5-16; 8:45 am]
 BILLING CODE 4140-01-P